

Jeannine S Mccune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2775685/publications.pdf>

Version: 2024-02-01

135
papers

5,103
citations

87723

38
h-index

110170

64
g-index

136
all docs

136
docs citations

136
times ranked

6175
citing authors

#	ARTICLE	IF	CITATIONS
1	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	0.6	174
2	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
3	Perception of Chemotherapy Side Effects Cancer versus Noncancer Patients. <i>Cancer Practice</i> , 1999, 7, 59-65.	0.8	161
4	Plasma Concentration Monitoring of Busulfan. <i>Clinical Pharmacokinetics</i> , 2000, 39, 155-165.	1.6	137
5	In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 356-366.	2.3	133
6	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
7	Development and Validation of a Novel Acute Myeloid Leukemiaâ€“Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
8	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2770-2777.	0.8	124
9	Potential of chemotherapy?herb interactions in adult cancer patients. <i>Supportive Care in Cancer</i> , 2004, 12, 454-462.	1.0	123
10	A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 495-505.	2.0	115
11	Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 167-173.	1.3	113
12	Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization. <i>Clinical Cancer Research</i> , 2014, 20, 754-763.	3.2	112
13	Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. <i>Journal of Clinical Investigation</i> , 2010, 120, 2345-2354.	3.9	101
14	Cancer Pain Survey. <i>Journal of Pain and Symptom Management</i> , 1998, 15, 275-284.	0.6	98
15	Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 853-862.	2.0	89
16	Busulfan in hematopoietic stem cell transplant setting. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 957-969.	1.5	89
17	The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2002, 30, 814-822.	1.7	88
18	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584.	2.0	88

#	ARTICLE	IF	CITATIONS
19	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE, 2018, 13, e0198389.	1.1	86
20	Optimal Prevention of Seizures Induced by High-Dose Busulfan. Pharmacotherapy, 2008, 28, 1502-1510.	1.2	79
21	A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2005, 11, 465-471.	2.0	78
22	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Research, 2015, 75, 3738-3746.	0.4	76
23	Personalized Dosing of Cyclophosphamide in the Total Body Irradiation Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy. Clinical Pharmacology and Therapeutics, 2009, 85, 615-622.	2.3	73
24	Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. Natural Product Reports, 2019, 36, 1196-1221.	5.2	72
25	Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. International Journal of Medical Informatics, 2014, 83, 473-483.	1.6	71
26	Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood, 2005, 106, 4381-4388.	0.6	69
27	Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2013, 19, 1033-1039.	2.0	65
28	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. , 2019, 201, 25-38.		65
29	Rapid Advances in Immunotherapy to Treat Cancer. Clinical Pharmacology and Therapeutics, 2018, 103, 540-544.	2.3	64
30	Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?. Genetics in Medicine, 2005, 7, 380-389.	1.1	62
31	Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2012, 18, 265-272.	2.0	59
32	The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. Oncologist, 2016, 21, 320-326.	1.9	59
33	CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION. Drug Metabolism and Disposition, 2005, 33, 1074-1081.	1.7	56
34	Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (<i>Camellia sinensis</i>) as a Case Study. Journal of Natural Products, 2017, 80, 1457-1466.	1.5	53
35	Lack of Gender Differences and Large Intrasubject Variability in Cytochrome P450 Activity Measured by Phenotyping with Dextromethorphan. Journal of Clinical Pharmacology, 2001, 41, 723-731.	1.0	52
36	Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. Scientia Pharmaceutica, 2010, 78, 473-481.	0.7	44

#	ARTICLE	IF	CITATIONS
37	Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo. <i>Drug Metabolism and Disposition</i> , 2012, 40, 54-63.	1.7	42
38	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2016, 55, 525-550.	1.6	42
39	Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. <i>Anti-Cancer Drugs</i> , 2004, 15, 453-459.	0.7	41
40	Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach. <i>Clinical Cancer Research</i> , 2006, 12, 4888-4898.	3.2	40
41	Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 393-402.	1.0	40
42	Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 581-588.	1.3	38
43	Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1429-1438.	1.0	37
44	Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 105-113.	1.2	36
45	Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. <i>American Journal of Managed Care</i> , 2010, 16, 678-86.	0.8	36
46	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2018, 34, 284-291.	1.1	35
47	Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 88-102.	1.0	34
48	Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 264-275.	1.0	34
49	Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 373-379.	1.1	33
50	Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 760-764.	2.0	32
51	Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. <i>Clinical Pharmacokinetics</i> , 2016, 55, 551-593.	1.6	32
52	Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-An ACCRU Network study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 611-611.	0.8	32
53	Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 298-308.	2.3	31
54	Current Status of Cetuximab for the Treatment of Patients with Solid Tumors. <i>Annals of Pharmacotherapy</i> , 2006, 40, 241-250.	0.9	31

#	ARTICLE	IF	CITATIONS
55	Appropriateness of maximum-dose guidelines for vincristine. American Journal of Health-System Pharmacy, 1997, 54, 1755-1758.	0.5	30
56	Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 270-276.	0.6	30
57	Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 621-626.	0.8	30
58	The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer, 2005, 104, 2054-2062.	2.0	29
59	Development of a Population Pharmacokinetics-Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration. Journal of Clinical Pharmacology, 2010, 50, 1292-1300.	1.0	29
60	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1159-1166.	2.0	29
61	Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. Journal of Clinical Pharmacology, 2012, 52, 586-594.	1.0	27
62	Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. Journal of Biomedical Informatics, 2015, 55, 249-259.	2.5	27
63	The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2005, 56, 578-584.	1.1	26
64	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 2021, 138, 387-400.	0.6	26
65	Influence of Age Upon Ifosfamide-Induced Nephrotoxicity. Pediatric Blood and Cancer, 2004, 42, 427-432.	0.8	23
66	Establishment of Long-Term Tolerance to SRBC in Dogs by Recombinant Canine CTLA4-Ig. Transplantation, 2009, 88, 317-322.	0.5	23
67	Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoietic Cell Transplant Recipients. Journal of Proteome Research, 2016, 15, 2802-2811.	1.8	23
68	A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clinical Cancer Research, 2009, 15, 5280-5287.	3.2	22
69	Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (<i>Camellia</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 10 In Vivo Extrapolation. Drug Metabolism and Disposition, 2018, 46, 552-560.	1.7	22
70	Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children. Pediatric Hematology and Oncology, 2014, 31, 731-742.	0.3	21
71	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. Biology of Blood and Marrow Transplantation, 2014, 20, 1121-1129.	2.0	21
72	Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage. International Journal of Environmental Research and Public Health, 2020, 17, 493.	1.2	21

#	ARTICLE	IF	CITATIONS
73	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
74	Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1041-1045.	1.7	20
75	Myalgias and arthralgias associated with paclitaxel. <i>Oncology</i> , 2003, 17, 271-7; discussion 281-2, 286-8.	0.4	20
76	Pharmacokinetics of Oral Mycophenolate Mofetil in Dog: Bioavailability Studies and the Impact of Antibiotic Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1352-1354.	2.0	19
77	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 391-401.	1.1	19
78	Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1046-1052.	1.7	19
79	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
80	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	2.9	19
81	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. <i>Blood</i> , 2019, 134, 211-215.	0.6	18
82	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
83	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration-Time Curve in Hematopoietic Cell Transplantation Recipients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1654-1664.	1.0	17
84	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 263-272.	1.1	17
85	Prediction of intravenous busulfan clearance by endogenous plasma biomarkers using global pharmacometabolomics. <i>Metabolomics</i> , 2016, 12, 1.	1.4	17
86	Granulocyte Colony-Stimulating Factor Use in Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2000, 34, 851-857.	0.9	16
87	Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 839-847.	0.8	16
88	A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 820, 243-250.	1.2	15
89	Imatinib inhibition of fludarabine uptake in T-lymphocytes. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 735-739.	1.1	15
90	Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 344-349.	0.5	15

#	ARTICLE	IF	CITATIONS
91	Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. <i>Pharmacogenomics Journal</i> , 2008, 8, 248-255.	0.9	14
92	Colony-stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non-small Cell Lung Cancer Who Were Receiving Chemotherapy. <i>Pharmacotherapy</i> , 2012, 32, 7-19.	1.2	14
93	Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 991-1000.	1.1	14
94	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 85-96.	1.1	14
95	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
96	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 67-75.	1.1	13
97	Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics. <i>Bone Marrow Transplantation</i> , 2015, 50, 165-172.	1.3	13
98	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 461-470.	0.6	13
99	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 711-7.	0.3	13
100	Cyclophosphamide disposition in an anephric child. <i>Pediatric Blood and Cancer</i> , 2006, 46, 99-104.	0.8	12
101	Patterns of blood product use among patients with myelodysplastic syndrome. <i>Vox Sanguinis</i> , 2012, 102, 331-337.	0.7	12
102	Concepts and Applications of Information Theory to Immuno-Oncology. <i>Trends in Cancer</i> , 2021, 7, 335-346.	3.8	12
103	Topotecan Disposition in an Anephric Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 596-600.	0.3	11
104	A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1104-1112.	1.7	11
105	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. <i>Lancet Haematology</i> , 2016, 3, e516-e525.	2.2	10
106	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 607-618.	1.1	9
107	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1802-1807.	2.0	9
108	Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 37-43.	0.5	8

#	ARTICLE	IF	CITATIONS
109	A Pilot Study of Website Information Regarding Aromatase Inhibitors: Dietary Supplement Interactions. <i>Journal of Alternative and Complementary Medicine</i> , 2011, 17, 1043-1049.	2.1	8
110	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. <i>Pharmacological Reviews</i> , 2021, 73, 847-859.	7.1	8
111	Intracellular disposition of fludarabine triphosphate in human natural killer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 959-964.	1.1	7
112	Health Care Use and Primary Prophylaxis with Colony-Stimulating Factors. <i>Value in Health</i> , 2011, 14, 247-252.	0.1	7
113	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1544-1552.	2.0	7
114	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 657-663.	1.0	7
115	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021, 20, 684-694.	1.8	6
116	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015, 126, 532-532.	0.6	6
117	Pharmacometabonomic association of cyclophosphamide 4-hydroxylation in hematopoietic cell transplant recipients. <i>Clinical and Translational Science</i> , 2022, 15, 1215-1224.	1.5	6
118	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 48-56.	2.0	5
119	Developing and Using Therapeutics for Emerging Infections. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 346-351.	2.3	4
120	Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29203.	0.8	4
121	Pharmacological Considerations of Primary Alkylators. <i>Cancer Treatment and Research</i> , 2002, 112, 323-345.	0.2	4
122	The essential research curriculum for doctor of pharmacy degree programs - 2021. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	4
123	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study. <i>Journal of Clinical Oncology</i> , 2016, 34, 10528-10528.	0.8	3
124	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. <i>Clinical and Translational Science</i> , 2022, 15, 322-329.	1.5	3
125	A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2005, 23, 511-519.	0.6	2
126	Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 of a Prospective Clinical Trial. <i>Blood</i> , 2009, 114, 1175-1175.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.. Journal of Clinical Oncology, 2015, 33, 6612-6612.	0.8	2
128	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplantation, 2021, , .	1.3	2
129	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. Bone Marrow Transplantation, 2021, 56, 726-729.	1.3	1
130	Impact of skeletal-related events on survival in patients with prostate cancer metastatic to bones.. Journal of Clinical Oncology, 2015, 33, 223-223.	0.8	1
131	Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S406.	2.0	0
132	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
133	Abstract P4-08-01: Assessing the safety and feasibility of efficient hypothesis testing in patients with metastatic triple negative breast cancer. , 2015, , .		0
134	Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2016, 34, 10560-10560.	0.8	0
135	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. Blood, 2018, 132, 620-620.	0.6	0